Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular Degeneration

Moshfeghi, Andrew A; Rosenfeld, Philip J.; Puliafito, Carmen A.; Michels, Stephan; Marcus, Erin N.; Lenchus, Joshua D.; Venkatraman, Anna S.

doi:10.1016/j.ophtha.2006.05.070

Cited by 188 publications

(77 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There has been only one study of intravenous bevacizumab in eye diseases; specifically, the treatment of 18 patients with neovascular AMD [64]. In this uncontrolled study a dose of 5 mg/kg was used, and one or two additional doses were given at 2 week intervals.…”

Section: Results Of Clinical Trials Using Anti-vegf Drugsmentioning

confidence: 99%

Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy

2008

View full text Add to dashboard Cite

show abstract

Section: Results Of Clinical Trials Using Anti-vegf Drugsmentioning

confidence: 99%

Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy

2008

View full text Add to dashboard Cite

show abstract

“…Two articles showed the results of the same study [34,35]. Of these two, the article with the largest series of patients and longest follow-up period was included in this review [35].…”

Section: Resultsmentioning

confidence: 99%

“…Of these two, the article with the largest series of patients and longest follow-up period was included in this review [35]. In this study the effect of intravenous bevacizumab in AMD was studied.…”

Section: Resultsmentioning

confidence: 99%

A systematic review on the effect of bevacizumab in exudative age-related macular degeneration

Schouten

Heij

Webers

et al. 2008

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

Aim To provide evidence for the effect of bevacizumab on visual acuity (VA) and central retinal thickness (CRT) in exudative age-related macular degeneration Methods A systematic review of all articles of bevacizumab for exudative AMD was conducted. Articles published up to March 2008 were identified in Medline, Embase, the Cochrane Controlled Trials Register and references from included articles. Search terms were "Bevacizumab or Avastin" and "Macula* or ARMD or AMD or intra(-) vitreal or intra(-)vitreous". Three observers participated in the data retrieval and assignment of the quality scores. Results A total of 561 articles were retrieved. Three randomised controlled trials (RCT) and 23 before-and-after studies of patients (n=1,435) who had received bevacizumab were published. Inclusion criteria varied. Lack of masking was the main methodological shortcoming. These RCTs showed that bevacizumab is more effective than PDT. Bevacizumab was given intravenously or as intravitreal injection. The latter was given once, or repeatedly every 4 weeks, and with or without additional injection when a recurrence occurred, mostly based on visual acuity and/or findings from optical coherence tomography. After intravenous administration, the weighted mean change in VA was +12.8 ETDRS letters (range +11 to +14) and the weighted mean change for CRT was −129 μm (range −100 to −202). For the 23 studies with intravitreal injections, the change in VA was +8.6 letters (range +2 to +26) and the change in CRT was −90 μm (range −46 to −190). The incidence of adverse events was low. The change in VA was 2.7 letters higher for studies with a higher quality vs lower quality. Conclusion Visual acuity improves and central retinal thickness decreases in patients with exudative AMD after bevacizumab. There is no reasonable doubt that this is caused by bevacizumab. It is likely that a randomised controlled trial will show that bevacizumab is equivalent in effect to ranibizumab, which showed a change in ETDRS of +5.9 letters for occult or minimally classic CNV and +9.8 letters for classic CNV after three monthly injections in two large RCTs.

show abstract

“…Systemic bevacizumab was used initially in the treatment of subfoveal choroidal neovascularisation (CNV) in AMD with encouraging results. 1 The use of intravitreal bevacizumab followed and it has been estimated that since then more than 10 000 patients have been treated worldwide. 2 This study describes our experience in the use of intravitreal bevacizumab before the licensing of pegaptanib by the European Agency for the Evaluation of Medicinal Products.…”

Section: Introductionmentioning

confidence: 99%

Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results

Cleary

Jungkim

Ravikumar

et al. 2007

Eye

View full text Add to dashboard Cite

Purpose To evaluate 6-and 9-month follow-up data including the effect on vision and anatomic outcome in patients treated with intravitreal bevacizumab for neovascular age-related macular degeneration (AMD). Study design Interventional consecutive retrospective case series. Patients received intravitreal bevacizumab for the treatment of neovascular AMD including choroidal neovascular membranes, pigment epithelial detachment, and macular haemorrhage. Ophthalmic evaluation included log MAR or Snellen acuity, ophthalmic examination, optical coherence tomography, and fluorescein angiography. Repeat injections were given in the presence of persistent leakage or retinal oedema. Change in vision and foveal thickness from baseline was evaluated using the paired Student's t-test.

show abstract

Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular Degeneration

Cited by 188 publications

References 19 publications

Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy

Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy

A systematic review on the effect of bevacizumab in exudative age-related macular degeneration

Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results

Contact Info

Product

Resources

About